Genmab A/S Q3 2026 Earnings Recap

The stock fell 2.7% after earnings, a roughly flat reaction under the stated threshold. Revenue rose 22% and adjusted operating profit 9%, while the call also highlighted positive phase III readouts and commercial growth.

Key Takeaways

• Total revenue increased 22% and adjusted operating profit increased 9%, according to management.
• EPKINLY sales were $491 million for the first nine months, up 47% year over year.
• TIVDAK sales were $131 million for the first nine months, up 9% year over year.
• Genmab reported positive phase III results for EPKINLY in frontline DLBCL, Rina-S in platinum-resistant ovarian cancer, and petosemtamab in first-line head and neck cancer.
• The next petosemtamab milestone, the LiGeR-HN2 trial in the second- and third-line setting, is expected in the first quarter of 2027.